Anaplastic Lymphoma Kinase-positive Large B-cell Lymphoma: Clinico-pathological Study of 17 Cases with Review of Literature

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 1

PMID 28665943

Citations 6

Authors

Xiang-Nan Jiang

Bao-Hua Yu

Wei-Ge Wang

Xiao-yan Zhou

Xiao-Qiu Li

Affiliations

Soon will be listed here.

Abstract

We retrospectively analysed 17 cases of anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+, LBCL) according to the morphological, immunohistochemical, molecular and clinical features, using which we intend to elucidate the clinicopathological characteristics of this rare entity. In this study, all cases de facto share common features that defined them as a single entity, and various characteristics may expand the spectrum. Among 15 cases, 60% followed an aggressive clinical course with advanced stage and high IPI scores; the median survival of these patients was only 8 months. An analysis showed that both the IPI score and the Ann Arbor stage were significant prognostic factors. Most patients received a chemotherapy regimen including CHOP, CHOEP, EPOCH, and CVAD, and some also underwent localized radiotherapy. However, ALK+, LBCL cases display a dismal clinical outcome and can only be cured with conventional chemotherapy protocols at the stage of localized disease. Novel front-line intensive chemotherapy regimens should therefore be evaluated in this group of patients.

Citing Articles

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review.

Wang H, Bai J, Zhang B, Pei Z, Zhao Y, Gu J Front Oncol. 2025; 14:1480880.

PMID: 39906668 PMC: 11790561. DOI: 10.3389/fonc.2024.1480880.

ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression.

Baker J, Zadeh S, Aguilera N J Hematop. 2024; 17(2):109-114.

PMID: 38573563 PMC: 11127819. DOI: 10.1007/s12308-024-00582-x.

Primary anaplastic lymphoma kinase-positive large B-cell lymphoma of the left bulbar conjunctiva: A case report.

Guo X, Li C, Cao H, Yang G World J Clin Cases. 2024; 12(3):657-664.

PMID: 38322452 PMC: 10841960. DOI: 10.12998/wjcc.v12.i3.657.

fusion in ALK positive large B-cell lymphoma: a case report and review of literature.

Xiao A, Shahmarvand N, Nagy A, Kumar J, Van Ziffle J, Devine P Front Oncol. 2023; 13:1174606.

PMID: 37305584 PMC: 10248242. DOI: 10.3389/fonc.2023.1174606.

Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma: a rare cause of ileal intussusception.

OHare E, Thekkinedath A, Ngu L, McCullagh P BMJ Case Rep. 2022; 15(12).

PMID: 36585041 PMC: 9809244. DOI: 10.1136/bcr-2022-253239.

References

DAmore E, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E . STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol. 2013; 37(5):780-6. DOI: 10.1097/PAS.0b013e318287791f. View

Laurent C, Do C, Gascoyne R, Lamant L, Ysebaert L, Laurent G . Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009; 27(25):4211-6. DOI: 10.1200/JCO.2008.21.5020. View

Cheng M, Quail M, Gingrich D, Ott G, Lu L, Wan W . CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2011; 11(3):670-9. DOI: 10.1158/1535-7163.MCT-11-0776. View

Yu H, Huang J, Wang C, Shi D . [ALK-positive large B-cell lymphoma: report of a case]. Zhonghua Bing Li Xue Za Zhi. 2011; 40(8):561-2. View

Morgan E, Nascimento A . Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol. 2012; 2012:529572. PMC: 3299366. DOI: 10.1155/2012/529572. View

Wass M, Behlendorf T, Schadlich B, Mottok A, Rosenwald A, Schmoll H . Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. Eur J Haematol. 2013; 92(3):268-70. DOI: 10.1111/ejh.12240. View

Stachurski D, Miron P, Al-Homsi S, Hutchinson L, Lee Harris N, Woda B . Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24. Hum Pathol. 2007; 38(6):940-5. DOI: 10.1016/j.humpath.2006.12.019. View

Rudzki Z, Rucinska M, Jurczak W, Skotnicki A, Maramorosz-Kurianowicz M, Mruk A . ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol. 2005; 56(1):37-45. View

Bedwell C, Rowe D, Moulton D, Jones G, Bown N, Bacon C . Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. Haematologica. 2010; 96(2):343-6. PMC: 3031708. DOI: 10.3324/haematol.2010.031484. View

10.

Van Roosbroeck K, Cools J, Dierickx D, Thomas J, Vandenberghe P, Stul M . ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica. 2010; 95(3):509-13. PMC: 2833084. DOI: 10.3324/haematol.2009.014761. View

11.

Onciu M, Behm F, Downing J, Shurtleff S, Raimondi S, Ma Z . ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003; 102(7):2642-4. DOI: 10.1182/blood-2003-04-1095. View

12.

Galkin A, Melnick J, Kim S, Hood T, Li N, Li L . Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2006; 104(1):270-5. PMC: 1765448. DOI: 10.1073/pnas.0609412103. View

13.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C . Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One. 2011; 6(4):e18436. PMC: 3072987. DOI: 10.1371/journal.pone.0018436. View

14.

Beltran B, Castillo J, Salas R, Quinones P, Morales D, Hurtado F . ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009; 2:11. PMC: 2651189. DOI: 10.1186/1756-8722-2-11. View

15.

Li K, Tipps A, Wang H . Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. Int J Clin Exp Pathol. 2011; 4(2):190-6. PMC: 3037206. View

16.

Chen Y, Hung L, Shan Y, Chang K . ALK-positive large B-cell lymphoma presenting with jejunal intussusception. Eur J Haematol. 2012; 90(3):261. DOI: 10.1111/ejh.12031. View

17.

Pan Z, Hu S, Li M, Zhou Y, Kim Y, Reddy V . ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. Am J Surg Pathol. 2016; 41(1):25-38. DOI: 10.1097/PAS.0000000000000753. View

18.

Gascoyne R, Lamant L, Martin-Subero J, Lestou V, Lee Harris N, Muller-Hermelink H . ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003; 102(7):2568-73. DOI: 10.1182/blood-2003-03-0786. View

19.

Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C . A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol. 2003; 27(11):1473-6. DOI: 10.1097/00000478-200311000-00012. View

20.

Lee H, Kim K, Kim W, Ko Y . ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol. 2008; 26(2):108-13. DOI: 10.1002/hon.841. View